Immatics NVIMTX +5.96%60 PS Ratio is 29.28 as of Jul. 01, 2026, which is 138% above its 10-year median of 12.29. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $3.57 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 935 Biotechnology companies, Immatics NV ranks worse than 71.87% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Immatics NV's share price is $10.13.
Immatics NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35. Hence, Immatics NV's PS Ratio for today is 29.28.
The historical rank and industry rank for Immatics NV's PS Ratio or its related term are showing as below:
IMTX'
s PS Ratio Range Over the Past 10 Years
Min: 2.41 Med: 12.29 Max: 36.44
Current: 29.28
During the past 8 years, Immatics NV's highest PS Ratio was 36.44. The lowest was 2.41. And the median was 12.29.
IMTX's PS Ratio is ranked worse than 71.87% of 935
companies
in the Biotechnology industry
Industry Median: 9.37
vs IMTX: 29.28
Immatics NV revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Immatics NV was -74.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -44.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -3.70% per year.
During the past 8 years, Immatics NV's highest 3-Year average Revenue per Share Growth Rate was 109.40% per year. The lowest was -44.20% per year. And the median was 34.80% per year.
Back to Basics: PS Ratio
Immatics NV (NAS:IMTX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Immatics NV PS Ratio Related Terms
Immatics NV PS Ratio Historical Data
* Premium members only.
The historical data trend for Immatics NV's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immatics NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immatics NV PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immatics NV's PS Ratio distribution charts can be found below:
* The bar in red indicates where Immatics NV's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Immatics NV's Share Price of today is $10.13. Immatics NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Immatics NV (IMTX) has a PS Ratio of 29.28 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Immatics NV and its competitors. This is 138% above median its historical median of 12.29. Over the past decade, Immatics NV's PS Ratio has ranged from 2.41 to 36.44. According to the industry distribution chart, Immatics NV ranks #672 out of 935 companies in the Biotechnology industry, placing it in the top 71.9%.
Is Immatics NV's PS Ratio too high?
Immatics NV's current PS Ratio of 29.28 is 138% above median its 10-year median of 12.29. Over the past 10 years, this metric has ranged from a low of 2.41 to a high of 36.44. The Biotechnology industry median PS Ratio is 9.37. Immatics NV's value of 29.28 is 212.5% above this industry median. Based on the distribution chart, Immatics NV ranks #672 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's PS Ratio compare to MNKD and JBIO?
According to the Biotechnology industry distribution chart, Immatics NV ranks #672 out of 935 companies for PS Ratio. This places Immatics NV in the lower half of its industry. The industry median PS Ratio is 9.37. Immatics NV's value of 29.28 is 212.5% above this benchmark. Historically, Immatics NV's own PS Ratio has ranged from 2.41 to 36.44 over the past decade. While the company's 10-year median is 12.29 vs. the industry median of 9.37, Immatics NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.37, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immatics NV's current PS Ratio of 29.28 is 212.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Immatics NV and its competitors. For the Biotechnology industry, the median PS Ratio is 9.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immatics NV's current PS Ratio is 29.28, which is 138% above median its own 10-year median of 12.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.57, compared to a current price of $10.13 — trading 183.8% above its estimated fair value. The current PS Ratio is 29.28, which is 138% above median its 10-year median of 12.29 and 212.5% above the Biotechnology industry median of 9.37. Immatics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Immatics NV (IMTX), the current PS Ratio is 29.28 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immatics NV (IMTX) Overvalued in 2026?
Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued.
The current stock price of $10.13 is trading 183.8% above its estimated GF Value™ of $3.57.
GuruFocus considers Immatics NV to be Significantly Overvalued.
Key valuation signals for IMTX:
PS Ratio: 29.28 (138% above median its 10-year median of 12.29)
GF Value™: $3.57 vs. price of $10.13 (183.8% above fair value)
Industry Position: 212.5% above the Biotechnology median (#672 of 935)
No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score
Get the complete analysis for IMTX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMTX has been successfully added to your 
